Quest Diagnostics Stock News

Robeco Institutional Asset Management B.V. raised its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 63.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 544,088 shares of the medical research companys stock after purchasing an additional 212,046 shares during the quarter. Robeco []

Quest Diagnostics Incorporated (NYSE:DGX) has been given a consensus rating of Buy by the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that []

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Quest Diagnostics Incorporated (NYSE:DGX) SVP Catherine T. Doherty sold 37,565 shares of Quest Diagnostics stock in a transaction on Monday, November 29th. The shares were sold at an average price of $156.81, for a total transaction of $5,890,567.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available []

Paragon Capital Management Ltd boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,666 shares of the medical research companys stock after acquiring an additional 114 shares during the []

Shares of Quest Diagnostics Incorporated (NYSE:DGX) have earned a consensus recommendation of Buy from the eleven research firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have []

According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposur

According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposur

Genesee Capital Advisors LLC acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,161 shares of the medical research companys stock, valued at approximately $314,000. Several other institutional investors have also recently []

Jeremy Grantham’s 13F portfolio value increased from $20.05B to $20.22B this quarter. The largest three positions are Microsoft, Alphabet and Apple.

Becker Capital Management Inc. raised its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 6.8% during the 3rd quarter, Holdings Channel reports. The firm owned 121,654 shares of the medical research companys stock after buying an additional 7,737 shares during the quarter. Becker Capital Management Inc.s holdings in Quest Diagnostics were worth $17,678,000 at the end []

Global Urodynamic Testing Market Synopsis: It gets easy to make informed decisions that eventually provide maximum ROI from the marketing expenditures with the winning Urodynamic Testing Market report. A well-equipped global delivery center and highly-competent research team leads to creation of

JGP Wealth Management LLC lowered its position in Quest Diagnostics Incorporated (NYSE:DGX) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,389 shares of the medical research company’s stock after selling 195 shares during the period. Quest Diagnostics […]

Hennessy Advisors Inc. decreased its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 1.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,400 shares of the medical research companys stock after selling 400 shares during the period. Hennessy Advisors Inc.s holdings in []